Fulvestrant, the injectable standard
Degrading the estrogen receptor has meant a clinic-administered injection of fulvestrant, a drug BioPharma Dive describes as decades old. Oral SERDs were designed to replace it with a once-daily pill.
The first oral SERDs reached market only for ESR1-mutant patients, so fulvestrant stayed in wide use.
No oral SERD has displaced the injection. Roche's drug is the first in the class to show a benefit in the adjuvant setting.
Wilserdly's sales case rests on moving injection patients to a pill and on treating patients fulvestrant cannot reach.
